E2006

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Metabolism and Excretion

Conditions

Metabolism and Excretion

Trial Timeline

Feb 1, 2014 → May 1, 2014

About E2006

E2006 is a phase 1 stage product being developed by Eisai for Metabolism and Excretion. The current trial status is completed. This product is registered under clinical trial identifier NCT02046213. Target conditions include Metabolism and Excretion.

What happened to similar drugs?

5 of 20 similar drugs in Metabolism and Excretion were approved

Approved (5) Terminated (2) Active (15)
cyclosporine micro-emulsionNovartisApproved
Fluvastatin sodiumNovartisApproved
🔄liraglutide + placeboNovo NordiskPhase 3
🔄Liraglutide 3.0 mg + PlaceboNovo NordiskPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT02089412Phase 1Completed
NCT02046213Phase 1Completed
NCT01673880Phase 1Completed

Competing Products

20 competing products in Metabolism and Excretion

See all competitors
ProductCompanyStageHype Score
mRNA-3704ModernaPhase 2
0
E2609EisaiPhase 1
29
AZD3480 + Placebo + Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin)AstraZenecaPhase 1
29
Xuezhikang Capsule + Atorvastatin Calcium TabletsAstraZenecaApproved
43
Rabeprazole or Esomeprazole or LanzoprazoleAstraZenecaPre-clinical
26
cyclosporine micro-emulsionNovartisApproved
35
Fluvastatin sodiumNovartisApproved
43
NNC0165-1562 + placeboNovo NordiskPhase 1
29
liraglutideNovo NordiskPhase 1
29
NNC9204-0530 + placeboNovo NordiskPhase 1
29
liraglutide + placeboNovo NordiskPhase 1
29
liraglutide + placebo + liraglutide + placeboNovo NordiskPhase 3
40
liraglutide + placeboNovo NordiskPhase 3
40
Liraglutide 3.0 mg + PlaceboNovo NordiskPhase 3
40
Semaglutide + Placebo (semaglutide)Novo NordiskPhase 3
40
liraglutide + orlistat + placeboNovo NordiskPhase 2
35
NNC 0070-0002-0453 + '2-0453 + placeboNovo NordiskPhase 1
21
NNC0194-0499 + PlaceboNovo NordiskPhase 1
29
Semaglutide + PlaceboNovo NordiskPhase 3
40
liraglutide + placeboNovo NordiskPhase 3
40